How AI can make echo labs more efficient | FDA approves new-look CLTI treatment | ACC takes on LDL screening

Advances in AI technology are expected to give physicians more time to provide high-quality care to their patients.

The new device, the first of its kind to gain FDA approval, was designed for patients who have no other endovascular or surgical options available to them.

The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues.

According to a loving tribute from Methodist Health System, Matthew Latacha, MD, was “well respected, admired and loved by patients, colleagues and staff.” The incident is still under investigation. 

We already screen patients for breast cancer and lung cancer on a regular basis. Why not establish screening programs for aortic stenosis?

Jackie Sohn, DO, discussed how POCUS is now incorporated into fellowship training programs and the different ways these handheld and smaller cart-based systems are being utilized in hospitals.

Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House. 

New research published in the Canadian Journal of Cardiology represents one the most detailed pictures to date of the long-term impact of ViV TMVR.

Under a new agreement, Strategic Radiology’s member practices will be able to use the ClearRead software solutions developed by Riverain Technologies. 

Three business professors believe the post-COVID “telehealth revolution” could work against its own implied promise to broaden care access.